Pfizer Price Increases Underscore Rebate Problem, HHS’ Hargan Says
Executive Summary
The Trump Administration remains convinced that rebates lead to high list prices and that reform of the system is needed, US HHS Deputy Secretary Eric Hargan emphasizes.
You may also be interested in...
House Oversight Drug Pricing Hearings Will Begin With Expert, Patient Witnesses
Manufacturers will avoid direct interrogation in first round, but Oversight Committee also seeking information from sponsors on reasons behind price increases. In US Senate, Susan Collins writes to HHS Secretary Alex Azar urging the department to move ahead with rebate reform.
DTC Ad Proposal: Biopharma, Advertisers Marshall Legal Arguments In Opposition
Industry comments urge CMS to withdraw proposed rule mandating list price disclosures in TV ads, citing legal conflicts.
The Inevitable Is Coming: Price Increases, Starting With Pfizer
Drug makers are planning for annual price increases, but with the industry in President Trump's crosshairs it remains to be seen if 2019 price hikes will be more modest than in the past. Pfizer confirmed plans to raise prices, but only on 10% of its portfolio.